Barinthus Biotherapeutics plc. (BRNS) Institutional Ownership

Ownership Summary

According to SEC filings for the period ending December 2025, Barinthus Biotherapeutics plc. (NASDAQ:BRNS) is held by 13 institutional firms.

• Institutional ownership in Barinthus Biotherapeutics edged down to 19.5% in December 2025, compared to 22.6% in September 2025.
• In percentage terms, this reflects as a holdings change of 3.83% quarter on quarter, and a decrease of 23.53% year over year.
• A review of institutional activity for Barinthus Biotherapeutics shows 5 of 13 filers increasing their positions, while 2 reduced their stake, and 6 remained unchanged.
• This class of investors increased its holdings in Barinthus Biotherapeutics to 7.90Mn shares for the 13F-cycle ending December 2025, up by 291.83K shares quarter on quarter, and down 1.82Mn shares year over year.
• With 5.20Mn shares, M&G Plc commands the largest institutional position in Barinthus Biotherapeutics as of December 31, 2025, equating to 12.85% of the company.
• Among the most significant buyers of Barinthus Biotherapeutics during December 2025 were CITADEL ADVISORS LLC (118.80K), Rangeley Capital, LLC (84.44K), RENAISSANCE TECHNOLOGIES LLC (76.80K), RHUMBLINE ADVISERS (11.69K), UBS Group AG (3.14K).
• Leading sellers of Barinthus Biotherapeutics stock in December 2025 included MORGAN STANLEY (1.54K), Baird Financial Group, Inc. (1.50K).
• The top 10 institutional holders of Barinthus Biotherapeutics for the quarter ending December 2025 included M&G Plc (5.20Mn), HSG Holding Ltd (1.42Mn), DC Funds, LP (642.20K), RENAISSANCE TECHNOLOGIES LLC (143.10K), Johns Hopkins University (122.24K), CITADEL ADVISORS LLC (118.80K), Baird Financial Group, Inc. (105.96K), Rangeley Capital, LLC (84.44K), HighTower Advisors, LLC (37.45K), RHUMBLINE ADVISERS (11.69K).